India, Oct. 27 -- Artiva Biotherapeutics (ARTV) has discontinued development of AlloNK (AB-101), its cell therapy for autoimmune diseases, and plans to reduce its workforce by approximately 94% while evaluating strategic alternatives.
AlloNK is an off-the-shelf natural killer cell therapy being studied in combination with rituximab for rheumatoid arthritis and other autoimmune diseases driven by B cells, a type of immune cell. Although updated data continued to show depletion and clinical activity, longer-term follow-up indicated that responses were not durable enough to support further development. The company will not initiate its planned Phase 3 trial or dose additional patients in ongoing studies.
The decision also follows two fatal s...